1. Scrip
  2. >>Business

Sosei Bolsters GPCR Focus With AbbVie Neurology Deal

Gets $40m Upfront

 
• By Ayisha Sharma

The Japanese firm has expanded its partnership with AbbVie into the neurology space, where it hopes to use its unique platform technology to develop up to three drug candidates targeting ‘challenging’ G protein-coupled receptor targets.  

Image Depicting Transmission Of Electric Impulses Between Two Nerve Cells
GPCRs Regulate Neurotransmission Between Nerve Cells • Source: Shutterstock

Sosei Co., Ltd is set to receive $40m upfront after pairing up with AbbVie Inc. to develop neurology drugs targeting receptors crucial to neurotransmitter regulation using its proprietary StaR technology to overcome challenges in CNS drug development.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business